Janus Henderson Group PLC Has $29.96 Million Holdings in LivaNova PLC $LIVN

Janus Henderson Group PLC raised its stake in LivaNova PLC (NASDAQ:LIVN) by 1,978.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 471,379 shares of the company’s stock after buying an additional 448,703 shares during the quarter. Janus Henderson Group PLC’s holdings in LivaNova were worth $29,961,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC increased its stake in LivaNova by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 24,257 shares of the company’s stock valued at $1,493,000 after buying an additional 11,066 shares during the last quarter. Peregrine Capital Management LLC bought a new stake in shares of LivaNova in the fourth quarter valued at $3,830,000. F m Investments LLC raised its stake in LivaNova by 46.9% in the 4th quarter. F m Investments LLC now owns 114,458 shares of the company’s stock valued at $7,043,000 after acquiring an additional 36,543 shares during the period. Tudor Investment Corp ET AL purchased a new position in shares of LivaNova in the third quarter worth about $1,746,000. Finally, Vanguard Group Inc. raised its position in shares of LivaNova by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock valued at $143,491,000 after purchasing an additional 34,812 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Stock Performance

LIVN opened at $80.14 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. The firm has a market capitalization of $4.40 billion, a price-to-earnings ratio of 41.10 and a beta of 0.86. The business has a 50 day simple moving average of $79.09 and a two-hundred day simple moving average of $70.19. LivaNova PLC has a one year low of $41.01 and a one year high of $85.27.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. During the same quarter in the previous year, the business posted $0.88 earnings per share. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Analysts predict that LivaNova PLC will post 3.73 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on LIVN. KeyCorp increased their target price on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. Zacks Research raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Barclays lifted their price target on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Mizuho boosted their price objective on shares of LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Finally, Robert W. Baird decreased their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $81.38.

Insider Activity at LivaNova

In other news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the transaction, the director owned 7,228 shares in the company, valued at $547,521. This trade represents a 19.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.35% of the stock is currently owned by insiders.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.